Choolip & Sciences
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Aptamer Sciences is a South Korean biotech listed on KOSDAQ that develops cancer treatments and diagnostic tools built around aptamers, short, lab-engineered molecules that bind tightly to specific biological targets, similar in concept to antibodies.
Its lead drug-development platform, called ApDC®, links aptamers to cancer-killing agents to create targeted therapies for solid and blood cancers, which the company aims to license out to larger pharmaceutical partners after establishing clinical proof of concept. Alongside drug development, it provides analytical testing services for biopharmaceuticals, including antibody drugs and peptides, to pharma companies and biotech ventures, and holds a diagnostic product designed to assess lung-cancer risk from blood protein markers.
Summary is AI-generated and may contain errors · figures from DART filings
The company was spun off from POSTECH, a South Korean research university, and entered the contract research services business through a merger completed in the most recent filing period.
Choolip & Sciences in five facts
What does Choolip & Sciences do?
Aptamer Sciences is a South Korean biotech listed on KOSDAQ that develops cancer treatments and diagnostic tools built around aptamers, short, lab-engineered molecules that bind tightly to specific biological targets, similar in concept to antibodies.
Where is Choolip & Sciences listed and in which sector?
Choolip & Sciences (Korean name: 츌립앤사이언스) trades under KRX code 291650 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Industrials sector, Commercial Services.
How large is Choolip & Sciences?
Its market capitalisation was US$58.6M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Choolip & Sciences's latest annual revenue and operating profit?
For fiscal year 2025, Choolip & Sciences reported revenue of US$2.6M, an operating loss of US$5.9M and a net loss of US$6.5M, per its annual report on DART (data retrieved from DART on 2026-06-03). Revenue was up 223.7% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-06-03
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Trading suspension (share consolidation/split registration)
Choolip & Sciences Inc.'s common shares will be suspended from trading starting 2026-07-22 due to a change or cancellation of electronic registration from a share consolidation, split, etc., with trading to resume the day after the new share certificates are listed.
M&A · Jul 16 - [Amended] Material event report (rights offering)
Choolip & Sciences updated the terms of a private placement (third-party allotment) to raise US$5.31M, about 10.1% of its market value.
Capital raise · Apr 6 - [Amended] Material event report (equity acquisition)M&A · Apr 1 · 2 versions
- [Amended] Material event report (rights offering)
Choolip & Sciences updated the terms of a private placement (third-party allotment) to raise US$7.94M, about 15.2% of its market value.
Capital raise · Apr 1 · 4 versions - [Amended] Material event report (rights offering)
Choolip & Sciences updated the terms of a private placement (third-party allotment) to raise US$5.39M, about 10.1% of its market value.
Capital raise · Mar 18 - Change of 30% or more in revenue or profit/loss structure (15% for large companies)
Choolip & Sciences reported separate results for FY2025: revenue of US$2.37M (+223.6% year on year), an operating loss of US$5.27M and a net loss of US$5.83M.
Earnings · Mar 6 - [Amended] Supply contract signed
Choolip & Sciences updated a previously disclosed supply contract with a company, now worth US$244K, about 32.87% of its recent annual revenue, running through Nov 2026.
Supply contract · Feb 10 - [Amended] Material event report (rights offering)Capital raise · Jan 30
- [Amended] Material event report (convertible bonds)Capital raise · Jan 21
- Material event report (convertible bonds)Capital raise · Jan 16